Experts Warn on Drug Firms' Obesity Campaigns
Experts Warn on Drug Firms' Obesity Campaigns
Experts Warn on Drug Firms' Obesity Campaigns
Key points
اہم نکات
मुख्य बातें
- Health experts are urging caution over campaigns by drug companies to destigmatise obesity, warning that firms profiting from weight-loss treatment could end up shaping public debate and national policy.
- Writing in The BMJ, Michael Viggars and colleagues say destigmatising obesity is the right thing to do, but point to Eli Lilly's UK 'Obesity Is a Disease' campaign, which presents obesity as a complex disease rather than a failure of willpower and invites people to check their body mass index and talk to a clinician.
- No drug is named in the adverts, yet Lilly's tirzepatide is now a principal obesity treatment.
- Health experts are urging caution over campaigns by drug companies to destigmatise obesity, warning that firms profiting from weight-loss treatment could end up shaping public debate and national policy.
- Writing in The BMJ, Michael Viggars and colleagues say destigmatising obesity is the right thing to do, but point to Eli Lilly's UK 'Obesity Is a Disease' campaign, which presents obesity as a complex disease rather than a failure of willpower and invites people to check their body mass index and talk to a clinician.
- No drug is named in the adverts, yet Lilly's tirzepatide is now a principal obesity treatment.
- Health experts are urging caution over campaigns by drug companies to destigmatise obesity, warning that firms profiting from weight-loss treatment could end up shaping public debate and national policy.
- Writing in The BMJ, Michael Viggars and colleagues say destigmatising obesity is the right thing to do, but point to Eli Lilly's UK 'Obesity Is a Disease' campaign, which presents obesity as a complex disease rather than a failure of willpower and invites people to check their body mass index and talk to a clinician.
- No drug is named in the adverts, yet Lilly's tirzepatide is now a principal obesity treatment.
Health experts are urging caution over campaigns by drug companies to destigmatise obesity, warning that firms profiting from weight-loss treatment could end up shaping public debate and national policy. Writing in The BMJ, Michael Viggars and colleagues say destigmatising obesity is the right thing to do, but point to Eli Lilly's UK 'Obesity Is a Disease' campaign, which presents obesity as a complex disease rather than a failure of willpower and invites people to check their body mass index and talk to a clinician. No drug is named in the adverts, yet Lilly's tirzepatide is now a principal obesity treatment. The authors say commercial interests behind such campaigns need careful scrutiny, so the conversation stays focused on patients rather than sales.
Health experts are urging caution over campaigns by drug companies to destigmatise obesity, warning that firms profiting from weight-loss treatment could end up shaping public debate and national policy. Writing in The BMJ, Michael Viggars and colleagues say destigmatising obesity is the right thing to do, but point to Eli Lilly's UK 'Obesity Is a Disease' campaign, which presents obesity as a complex disease rather than a failure of willpower and invites people to check their body mass index and talk to a clinician. No drug is named in the adverts, yet Lilly's tirzepatide is now a principal obesity treatment. The authors say commercial interests behind such campaigns need careful scrutiny, so the conversation stays focused on patients rather than sales.
Health experts are urging caution over campaigns by drug companies to destigmatise obesity, warning that firms profiting from weight-loss treatment could end up shaping public debate and national policy. Writing in The BMJ, Michael Viggars and colleagues say destigmatising obesity is the right thing to do, but point to Eli Lilly's UK 'Obesity Is a Disease' campaign, which presents obesity as a complex disease rather than a failure of willpower and invites people to check their body mass index and talk to a clinician. No drug is named in the adverts, yet Lilly's tirzepatide is now a principal obesity treatment. The authors say commercial interests behind such campaigns need careful scrutiny, so the conversation stays focused on patients rather than sales.
Most read
سب سے زیادہ پڑھی گئی
सबसे ज़्यादा पढ़ी गई
- Loading...
Get news in your inbox
خبریں اپنے ان باکس میں حاصل کریں
खबरें अपने इनबॉक्स में पाएं
One email when new stories are published. No spam, unsubscribe anytime.
نئی خبریں شائع ہونے پر ایک ای میل۔ کوئی سپیم نہیں، کسی بھی وقت ان سبسکرائب کریں۔
नई खबरें प्रकाशित होने पर एक ईमेल। कोई स्पैम नहीं, कभी भी अनसब्सक्राइब करें।